Response to Reuser | Zendy

Andrea Amalfitano | Zendy; Priya S. Kishnani | Zendy; YingTing Chen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Response to Reuser

Author(s) -

Andrea Amalfitano,

Priya S. Kishnani,

YingTing Chen

Publication year - 2012

Publication title -

genetics in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.509

H-Index - 128

eISSN - 1530-0366

pISSN - 1098-3600

DOI - 10.1038/gim.2012.81

Subject(s) - dosing , glycogen storage disease type ii , recombinant dna , regimen , glycogen storage disease , enzyme replacement therapy , medicine , disease , clinical trial , pediatrics , intensive care medicine , biology , biochemistry , gene

Fabry disease is a rare, X-linked, inherited lysosomal storage disorder that can be treated with the enzymes agalsidasealfa (Replagal) and agalsidase beta (Fabrazyme). Currently, there is a global shortage of agalsidase beta, and this has increased global demand for agalsidase alfa. We assess the feasibility of switching patients on agalsidase beta treatment to agalsidase alfa instead.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research